BUOY-1 builds on successful Phase 1 and Phase 2a data with GlyphAllo – a novel oral prodrug of allopregnanolone and a potential first-in-class treatment for MDD
Allopregnanolone has demonstrated rapid antidepressant and anxiolytic activity in clinical settings, but its clinical scope was previously constrained by limitations that Glyph™ is specifically designed to solve
Boston, MA – July 17, 2025 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that the first patient has been dosed in the Phase 2b BUOY-1 study of GlyphAlloTM (SPT-300 or Glyph Allopregnanolone) in major depressive disorder (MDD) with or without anxious distress. GlyphAllo is a novel, “Glyphed” oral prodrug of allopregnanolone, an endogenous molecule that has been shown to dampen stress. Allopregnanolone has been clinically validated in third-party trials as a rapidly acting antidepressant with anxiolytic effects, but its scope of clinical use was previously constrained by limitations that the GlyphTM platform is specifically designed to solve. GlyphAllo has the potential to be a first-in-class treatment for patients with MDD, including those with or without anxious distress.
“The initiation of BUOY-1 marks a significant milestone for Seaport’s pipeline, bringing us closer to a potential new treatment for major depression, which impacts around 280 million people globally – nearly 60 percent of whom also experience anxious distress,” said Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics. “This is an important step on our journey to deliver new treatments for patients living with depression, anxiety, and other neuropsychiatric conditions.”
BUOY-1 is a global, randomized, double-blind, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of GlyphAllo in adults with MDD, with or without anxious distress, a subtype of depression characterized by significant anxiety. The study is expected to enroll up to approximately 360 patients, randomized 1:1 to receive either GlyphAllo or placebo once-daily over a six-week treatment period. The primary endpoint of the study is the change from baseline at six weeks in the Hamilton Depression Rating Scale-17 (HAM-D-17), a gold-standard depression severity rating scale. Following the initial treatment period, eligible patients may enter an open-label extension phase, during which all participants will receive GlyphAllo for up to an additional six weeks.
“CNS clinical trials are inherently complex, and we are applying our team’s extensive expertise to implement a high-quality study,” said Antony Loebel, M.D., Chief Medical Officer, President of Clinical Development at Seaport Therapeutics. “We are confident that our rigorous clinical trial execution, including an emphasis on the quality of patient enrollment, will build on a proven mechanism and established clinical efficacy, to increase our likelihood of success in developing an effective treatment for patients with depression.”
The BUOY-1 study builds on a foundation of positive clinical data from Phase 1 and Phase 2a studies of GlyphAllo in healthy volunteers. In Phase 1, GlyphAllo demonstrated approximately nine times greater allopregnanolone exposure than that previously reported following oral dosing of allopregnanolone and reached similar exposures to the efficacious doses of IV-infused allopregnanolone. The two key measures used to determine allopregnanolone-associated brain activity, EEG beta frequency power and reduction in saccadic eye velocity, confirmed that GlyphAllo engaged with its target in a dose-dependent manner. The overall safety data, pharmacokinetics, and pharmacodynamic findings, along with non-clinical studies, support six-week dosing of GlyphAllo in BUOY-1.
In a Phase 2a proof-of-concept study in healthy volunteers using the Trier Social Stress Test (TSST), a validated clinical model of anxiety, GlyphAllo significantly reduced the stress hormone salivary cortisol at all post-TSST timepoints compared to placebo, meeting the primary endpoint with a p-value of 0.0001 and demonstrating that GlyphAllo regulates hypothalamic-pituitary-adrenal axis reactivity to acute stress. GlyphAllo was generally well-tolerated, with adverse events that were mostly mild and transient.
About the GlyphTM Platform
Glyph is Seaport’s proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism otherwise leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. For each program, Seaport leverages its Glyph platform to create unique sets of prodrugs with differentiated profiles, including lymphatic transport and conversion characteristics, as potential candidates to advance into preclinical and clinical proof-of-concept studies. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group. Advanced initially at PureTech Health and now at Seaport, Glyph has been applied to create therapeutic candidates for the Company’s pipeline resulting in new intellectual property, including composition of matter. The group and its collaborators have published research in Nature Metabolism, Frontiers in Pharmacology, Journal of Controlled Release and Molecular Pharmaceutics supporting the Glyph platform’s capabilities. See Glyph in action here.
About GlyphAlloTM (SPT-300 or Glyph Allopregnanolone)
GlyphAllo (SPT-300 or Glyph Allopregnanolone), an oral prodrug of allopregnanolone, is in clinical stage development for the treatment of major depressive disorder (MDD) with or without anxious distress. Allopregnanolone, an endogenous molecule that has been shown to dampen stress, has antidepressant and anxiolytic activity and sleep-promoting effects but poor oral bioavailability due to substantial first-pass hepatic metabolism. Allopregnanolone was previously only approved as an intravenous infusion, which limited the scope of its clinical use. A synthetic analog of allopregnanolone was previously evaluated in MDD and showed promise but may not retain the activity, potency and the breadth of the natural biological response of endogenous allopregnanolone. In a Phase 1 clinical study, GlyphAllo demonstrated oral bioavailability, tolerability and γ-aminobutyric-acid type A (GABAA) receptor target engagement in healthy volunteers. In a Phase 2a clinical study, GlyphAllo demonstrated initial proof-of-concept in the Trier Social Stress Test, a validated clinical model of anxiety in healthy volunteers. GlyphAllo is currently being evaluated in the Phase 2b BUOY-1 study for MDD, with or without anxious distress.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians, and key opinion leaders. For more information, please visit www.seaporttx.com
SPT-320, an oral prodrug of agomelatine, increased lymphatic transport to over 50 percent compared to less than one percent for agomelatine alone
SPT-320 increased plasma exposure of agomelatine by over 10-fold compared to agomelatine alone, demonstrating the delivery of therapeutically relevant agomelatine exposures at lower doses to potentially reduce or eliminate liver enzyme elevations
Company is progressing SPT-320 into the clinic as a novel treatment for generalized anxiety disorder
Boston, MA – April 24, 2025 – Seaport Therapeutics, a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the presentation of new preclinical data from SPT-320 at the Society of Biological Psychiatry (SOBP) Annual Meeting held on April 24-26 in Toronto, Canada. SPT-320 is a novel oral prodrug of agomelatine in development for the treatment of generalized anxiety disorder (GAD). The new findings demonstrate the potential of SPT-320 to deliver therapeutically relevant levels of agomelatine at lower doses, minimizing the impact on the liver, and addressing a key limitation that has previously held back agomelatine’s development in GAD.
Agomelatine, a clinically validated melatonin receptor agonist and serotonin 2C receptor antagonist, is an effective anxiolytic and antidepressant approved for the treatment of GAD in Australia and major depressive disorder (MDD) in Australia and the European Union (EU). In GAD, agomelatine has demonstrated statistically significant separation from placebo in four out of four third-party placebo-controlled studies and has better efficacy and tolerability – including reduced risk of abuse potential, sexual dysfunction, and weight gain – than standard of care drugs, like benzodiazepines or selective serotonin reuptake inhibitors (SSRIs). However, since over 90 percent of unmodified agomelatine is lost to first-pass liver metabolism, its use has been limited by dose-dependent liver enzyme elevations and the need for frequent liver monitoring. Using Seaport’s proprietary Glyph™ platform, SPT-320 is designed to overcome this limitation by shifting absorption toward the intestinal lymphatics, avoiding first-pass metabolism, and increasing systemic exposure of agomelatine.
In newly presented data from a series of preclinical proof-of-concept studies, SPT-320 exhibited enhanced lymphatic absorption and provided significantly higher systemic exposures of agomelatine compared to agomelatine alone. Specifically, oral dosing of SPT-320 resulted in over 50 percent of agomelatine being transported through the mesenteric lymphatics versus less than one percent for orally dosed agomelatine alone. The data also show that the oral dosing of SPT-320 increased plasma exposure of agomelatine by over 10-fold versus agomelatine alone, which would allow for a reduced dose, potentially eliminating liver enzyme elevations.
“We demonstrate, for the first time, that SPT-320 has the potential to deliver therapeutically relevant levels of agomelatine with a substantially lower dose, which could significantly reduce the impact on the liver while preserving the validated efficacy of agomelatine,” said Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, at Seaport Therapeutics. “These positive results further validate our Glyph prodrug platform and support initiating clinical development of SPT-320.”
The successful validation of SPT-320’s pharmacological profile in preclinical models supports Seaport’s progression into Phase 1 trials to further evaluate the safety, tolerability, and pharmacokinetics of SPT-320.
About SPT-320
SPT-320 is a novel oral prodrug of agomelatine has the potential to be the first new treatment for generalized anxiety disorder (GAD) in decades. Using the GlyphTM platform, SPT-320 was designed to bypass first-pass liver metabolism in order to lower the dose, reduce liver exposure, and reduce or eliminate the need for liver enzyme monitoring. Agomelatine is a clinically validated anxiolytic and antidepressant approved for GAD in Australia and major depressive disorder (MDD) in Australia and the European Union (EU). The use of agomelatine has been limited by high first-pass liver metabolism resulting in liver enzyme elevations in some patients and frequent, burdensome liver enzyme monitoring requirements.
About the GlyphTM Platform
Glyph is Seaport’s proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. For each program, Seaport uses Glyph to create sets of prodrugs with differentiated profiles, including lymphatic transport and conversion characteristics, as potential candidates to advance into preclinical and clinical proof-of-concept studies. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group. Advanced initially at PureTech Health and now at Seaport, Glyph has been applied to create therapeutic candidates for the Company’s pipeline resulting in new intellectual property, including composition of matter. The group and its collaborators have published research in Nature Metabolism, Frontiers in Pharmacology, Journal of Controlled Release and Molecular Pharmaceutics supporting the Glyph platform’s capabilities. See Glyph in action here.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians, and key opinion leaders. For more information, please visit www.seaporttx.com.
BOSTON, March 31, 2025 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that members of its management team will participate in the following upcoming investor conferences:
- 24th Annual Needham Healthcare Conference
- The Seaport management team was invited to present on Monday, April 7th at 3:45pm EDT. The live and archived webcast will be available under the Events section of the Company’s website at https://seaporttx.com/news-papers/. Management will also participate in one-on-one meetings at the conference.
- Citi Biotech Private Access Day
- The Seaport management team was invited to participate in one-on-one meetings at the virtual conference on April 24th.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com.
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience
BOSTON, March 11, 2025 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert “Bob” J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of Directors, such as FORTUNE 500 companies like BioMarin (NASDAQ: BMRN), where he also chairs the Audit Committee, and Henry Schein (NASDAQ: HSIC), a member of the S&P 500® index.
“We are excited to add Bob to our board. His financial and operational expertise perfectly complements the outstanding group of industry leaders on our board,” said Daphne Zohar, Founder and Chief Executive Officer of Seaport Therapeutics. “His deep understanding of the financial and operational intricacies of growing biotech companies will be an asset to Seaport as we advance our pipeline through important milestones, with the goal of delivering potentially life-changing neuropsychiatric medicines to patients and their families.”
Mr. Hombach served as the Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta (NYSE: BXLT), a $6 billion global biopharmaceutical company, until it was acquired by Shire plc. in 2016. He was instrumental in Baxalta’s successful spin off from its parent company, Baxter (NYSE: BAX), a nearly $18 billion company, where he previously served as Corporate Vice President and Chief Financial Officer. While at Baxter, he led the company’s strategic restructuring process and oversaw its venture capital investments through the Baxter Ventures Fund. In addition to his board positions at BioMarin and Henry Schein, Mr. Hombach is the Chair of the Audit Committee at Embecta (NASDAQ: EMBC), a global diabetes care company spun out of Becton Dickinson, and has held previous board positions at several other companies including Naurex, Inc., which was acquired by Allergan in 2015.
“Seaport is a new breed of company that is in a unique position to change the lives of patients with depression and anxiety disorders, and I am honored to contribute to the Company’s growth at such a pivotal time,” said Mr. Hombach. “Seaport’s scientific approach to advancing neuropsychiatric medicines is exciting and differentiated, and I look forward to supporting the Company’s commitment to maintaining the highest standards of financial oversight and governance as it continues its mission to make a difference in the lives of patients and their families impacted by these conditions.”
Mr. Hombach has earned numerous accolades, including recognition by IR Magazine as a Top 100 US CFO ranked seventh in both 2013 and 2014. He was also honored as a Board Leadership Fellow by the National Association of Corporate Directors (NACD). Mr. Hombach holds an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management and a B.S. in Finance cum laudefrom the University of Colorado.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com.
BOSTON, March 3, 2025 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that members of its management team will participate in the following upcoming investor conferences in March:
- Leerink Partners Global Healthcare Conference 2025
- The Seaport management team was invited to participate in one-on-one meetings at the conference on March 10-12th in Miami, FL.
- Stifel 2025 Virtual CNS Forum
- The Seaport management team was invited to present on Wednesday, March 19th at 2:00 – 2:25pm EDT. The live and archived webcast will be available under the Events section of the Company’s website at https://seaporttx.com/news-papers/.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com.
A key finding is that the number and frequency of clinician-administered assessments in MDD trials were positively correlated with an increased placebo response
Meta-analysis was presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Conference
BOSTON, February 21, 2025 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the presentation of a new meta-analysis exploring the impact of clinical trial design factors on the magnitude of placebo response in major depressive disorder (MDD) clinical trials. A poster highlighting this research was presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Conference held February 19 – 21, 2025, in Washington, D.C.
“CNS clinical trials present unique challenges, including high placebo responses. Analyzing past studies in a systematic way can help propel the entire field forward,” said Tony Loebel, M.D., Chief Medical Officer and President of Clinical Development at Seaport Therapeutics. “At Seaport, as we progress our pipeline of investigational antidepressants and anxiolytics, we believe our experience in the field, combined with our focus on clinically validated mechanisms, positions us to run better designed and informed trials that minimize placebo effects. Through sharing analyses such as these, we hope to contribute to broader knowledge in the field.”
Approximately 50-70 percent of MDD trials fail to meet their primary endpoint1. Participants in randomized, placebo-controlled trials often exhibit a high placebo response on clinical endpoints, making it difficult to assess the true effect of antidepressants2. The meta-analysis examined 27 industry-sponsored Phase 2-4, placebo-controlled MDD trials conducted in the past 10 years, all of which met strict inclusion criteria, including the use of the gold-standard Hamilton Depression Rating Scale (HAM-D) or Montgomery–Åsberg Depression Rating Scale (MADRS) primary endpoints.
In the meta-analysis, a higher number and frequency of clinician-administered assessments (CAAs) were associated with an increased placebo response even after accounting for factors like the number of trial sites, patient in-clinic visits, and treatment type. Other factors investigated include the number of trial sites and study duration, with neither showing a significant association with placebo effects. Higher baseline depression severity, as measured by HAM-D scores, appeared to have a modest association with a greater placebo change, though a limited subset of studies included baseline HAM-D scores.
This research provides new insights into factors potentially influencing the placebo effect and highlights the need for further investigation into the impact of design factors in MDD clinical trials.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com.
Footnotes
1.Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. NEJM, 358(3), 252–260.
2. Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002).
Published data shows new site of Glyph prodrug attachment demonstrated highest reported level of lymphatic transport to date of the studied immunomodulatory drug
New linkers display up to two-fold higher release in lymph nodes compared to top-performing previously reported linkers
Research builds on prior evidence supporting the versatility of Glyph platform
BOSTON, February 12, 2025 – Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the publication of new data showcasing the GlyphTM platform’s unique ability to enhance drug transport through the lymphatic system for increased therapeutic exposure. The paper, published in Molecular Pharmaceutics, is the first to show the impact of changing the drug attachment point of a lymph-directed prodrug on lymphatic drug transport and targeted drug exposure. It also deepens the evidence supporting Glyph’s ability to render a wide variety of molecules, including immunomodulators, more amenable to lymphatic transport and thus providing them with direct access to the immune system.
The study evaluated ways of modifying mycophenolic acid (MPA), an immunomodulatory drug, to improve its absorption through the lymphatic system, and increase its concentration in lymph nodes, shown in preclinical models. Specifically, a comparison between distinct attachment points on the same drug molecule was made. A newly examined phenol attachment point showed the highest lymphatic transport of MPA reported to date – approximately 55 percent – and up to two-fold higher release in lymph nodes compared to the previously reported acid attachment point. The research demonstrated the impact of linker characteristics on the extent of lymphatic transport and release in the lymph nodes. Overall, these results help to underscore the benefits of a tailored lymphatic-targeting prodrug design approach.
“This research expands our understanding of lymphatic delivery and offers new insights for more effectively designing drugs with higher exposures at their intended targets, including immunomodulatory drugs used to treat a wide range of diseases,” said Christopher Porter, Ph.D., an original Co-inventor of the Glyph technology and Director of the Monash Institute of Pharmaceutical Sciences at Monash University in Melbourne. “This study highlights the importance of integrating a careful and individualized balance of intestinal stability, transport efficiency and release in the mesenteric lymph nodes to maximize therapeutic exposures as part of a tailored prodrug design approach.”
With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group, including co-inventors Professor Porter and Jamie Simpson, Ph.D., who is now Head of Chemistry at Seaport Therapeutics.
“Our Glyph platform allows for a bespoke design approach, and this research reinforces the significance of the innovation behind our prodrug chemistry technology,” said Daniel Bonner, Ph.D., Co-founder, Senior Vice President, Platform, at Seaport Therapeutics. “Most importantly, Glyph has been clinically validated with demonstrated proof-of-concept data in humans and is being applied across Seaport’s pipeline of novel neuropsychiatric medicines, with enormous potential across a broad range of applications beyond CNS and neuropsychiatry.”
About the GlyphTM Platform
GlyphTM is Seaport’s proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group. Advanced initially at PureTech Health and now at Seaport, Glyph has been applied to create therapeutic candidates for the Company’s pipeline resulting in new intellectual property, including composition of matter. The group and its collaborators have published research in Nature Metabolism, Frontiers in Pharmacology, Journal of Controlled Release andMolecular Pharmaceutics supporting the Glyph platform’s capabilities. See Glyph in action here.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary GlyphTM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com.